Analysts: CBS May Buy Back Shares and 4 More Research Notes to Review Now

Acadia Pharmaceuticals¬†(NASDAQ:ACAD): Roth Capital is convinced that a Phase III trial of ACADIA’s pimavanserin for psychosis in Parkinson’s disease showed strong efficacy results supporting the $1 billion potential for the drug. The firm keeps its Buy rating and an $11 price target on the stock.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

ACAD